Xenopus GLP-1-based glycopeptides as dual glucagon-like peptide 1 receptor/glucagon receptor agonists with improved in vivo stability for treating diabetes and obesity

Li, Qiang; Yang, Qimeng; Han, Jing; LIU, Xiaohan; Fu, Junjie; Yin, Jian

doi:10.1016/s1875-5364(22)60196-1

Cited by 3 publications

(6 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increasing evidence is available on the dual agonisms of GLP-1 and glucagon [ 158 , 160 , 161 , 162 ]. Both glucagon and GLP-1 reduce appetite and promote weight loss; additionally, glucagon also increases energy expenditure.…”

Section: Future Perspectivesmentioning

confidence: 99%

GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives

Nevola

Epifani

Imbriani

et al. 2023

IJMS

View full text Add to dashboard Cite

To date, non-alcoholic fatty liver disease (NAFLD) is the most frequent liver disease, affecting up to 70% of patients with diabetes. Currently, there are no specific drugs available for its treatment. Beyond their anti-hyperglycemic effect and the surprising role of cardio- and nephroprotection, GLP-1 receptor agonists (GLP-1 RAs) have shown a significant impact on body weight and clinical, biochemical and histological markers of fatty liver and fibrosis in patients with NAFLD. Therefore, GLP-1 RAs could be a weapon for the treatment of both diabetes mellitus and NAFLD. The aim of this review is to summarize the evidence currently available on the role of GLP-1 RAs in the treatment of NAFLD and to hypothesize potential future scenarios.

show abstract

Section: Future Perspectivesmentioning

confidence: 99%

GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives

Nevola

Epifani

Imbriani

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…In a noteworthy experimental study by Li Q et al involving a diverse adult population (age >45 years, both males and females), GLP-1RAs emerged as a promising adjunct to glycemic control, exhibiting significant potential for weight reduction [ 7 ].…”

Section: Reviewmentioning

confidence: 99%

“…Individuals with T2DM lack proper incretin response [ 5 ]. By restoring the incretin effect and activating GLP-1 receptors in the brain, GLP-1 receptor agonists (GLP-1RAs) lower blood glucose levels and induce satiety, which also reduces appetite, increases fullness, and promotes weight loss [ 5 , 6 , 7 ]. GLP-1RAs reduce gastric emptying, decreasing food intake and postprandial glucagon and increasing glucose-dependent insulin secretion [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

“…Because of the high association of T2DM with obesity, weight loss should be considered to control T2DM [ 3 , 10 ]. GLP-1RAs have emerged as a powerful miracle to treat both T2DM and obesity concurrently [ 4 , 7 , 11 ].…”

Section: Introductionmentioning

confidence: 99%

“…GLP-1RAs play a vital role in fat redistribution in the body.2Li Q et al[7] 2022 Experimental Study Adult (>45 Y, M/F) GLP-1RAs assist in better glycemic control along with weight loss.Efpeglenatid improves glycemic control and weight reduction and later is also controlled in adults with no diabetes.Y, M/F)Low-carbohydrate meals along with proper education lead to weight loss in patients with type 2 diabetes.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Role of Glucagon-Like Peptide-1 Receptor Agonists on the Weight Loss of Individuals with Type 2 Diabetes: A Systematic Review

Irfan¹,

Pallipamu²,

Farhat³

et al. 2023

Cureus

View full text Add to dashboard Cite

Obesity is highly associated with type 2 diabetes mellitus (T2DM), both of which can be simultaneously treated with glucagon-like peptide-1 receptor agonists (GLP-1RAs). There are many antidiabetic drugs that can be used for the treatment of T2DM. These drugs have vast modes of action and therapeutic uses. However, they also have different side effects. Some of these side effects, such as weight changes, are sometimes desirable while others are not. This review examines the literature on how GLP-1RA affects both blood glucose and body weight in patients with T2DM and obesity. In this context, GLP-1RA plays a critical part by controlling not only the blood glucose level but also weight. We followed Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines and searched for articles from PubMed and Google Scholar databases that reported on T2DM, obesity, and GLP-1RA functions. We selected 13 articles that showed the benefits of GLP-1RA in managing both T2DM and obesity. Our review suggests that GLP-1RA is an innovative therapy that can address both conditions simultaneously.

show abstract

Clinical efficacy of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: A meta-analysis

Shi¹,

S²,

Ruan³

2023

Cell Mol Biol (Noisy-le-grand)

View full text Add to dashboard Cite

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been approved to treat type 2 diabetes mellitus (T2DM), which have been considered at the same treatment pattern point as basal insulin (BI). Thus, comprehensively comparing these drugs is conducive to informing the treatment decisions. In this context, this work was developed to evaluate the clinical efficacy and safety of GLP-1 RAs by comparing them with basal insulin. GLP-1 RAs were compared with basal insulin in adults with T2DM with inadequate oral anti-hyperglycemic drug control by searching related literature from MEDLINE, EMBASE, CENTRAL, and PubMed databases, which were published from established the datasets to October 2022. Data on hemoglobin A1c, body weight, and blood glucose were extracted and analyzed. The MD values of HbA1C, weight, and fasting blood glucose (FBG) change were -0.02, -1.37, and -1.68, respectively. Meanwhile, the OR of the hypoglycemia ratio was 0.33. In conclusion, GLP-1 RAs exhibited a great effect on blood glucose and weight control and a better effect on FBG control.

show abstract

Xenopus GLP-1-based glycopeptides as dual glucagon-like peptide 1 receptor/glucagon receptor agonists with improved in vivo stability for treating diabetes and obesity

Cited by 3 publications

References 38 publications

GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives

GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives

Role of Glucagon-Like Peptide-1 Receptor Agonists on the Weight Loss of Individuals with Type 2 Diabetes: A Systematic Review

Clinical efficacy of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: A meta-analysis

Contact Info

Product

Resources

About